Brokerages Set Royalty Pharma plc (NASDAQ:RPRX) Target Price at $41.67

Shares of Royalty Pharma plc (NASDAQ:RPRX) have been given a consensus rating of “Moderate Buy” by the six ratings firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $41.67.

A number of analysts have recently commented on the company. Citigroup lowered their target price on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, November 5th.

Royalty Pharma Price Performance

NASDAQ:RPRX opened at $24.92 on Wednesday. The firm’s fifty day moving average is $26.43 and its two-hundred day moving average is $27.15. The firm has a market cap of $14.68 billion, a price-to-earnings ratio of 12.91, a PEG ratio of 4.36 and a beta of 0.46. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.54 and a current ratio of 1.54. Royalty Pharma has a one year low of $24.05 and a one year high of $31.66.

Royalty Pharma Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 10th. Investors of record on Friday, November 15th were issued a $0.21 dividend. The ex-dividend date of this dividend was Friday, November 15th. This represents a $0.84 dividend on an annualized basis and a yield of 3.37%. Royalty Pharma’s payout ratio is 43.52%.

Institutional Trading of Royalty Pharma

Institutional investors have recently bought and sold shares of the business. Franklin Resources Inc. lifted its position in shares of Royalty Pharma by 5.0% during the 3rd quarter. Franklin Resources Inc. now owns 1,460,515 shares of the biopharmaceutical company’s stock valued at $40,705,000 after buying an additional 70,130 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Royalty Pharma during the third quarter worth $61,000. Sanctuary Advisors LLC lifted its holdings in Royalty Pharma by 78.9% during the third quarter. Sanctuary Advisors LLC now owns 41,466 shares of the biopharmaceutical company’s stock valued at $1,096,000 after purchasing an additional 18,288 shares in the last quarter. Hohimer Wealth Management LLC grew its position in shares of Royalty Pharma by 1.0% in the third quarter. Hohimer Wealth Management LLC now owns 145,357 shares of the biopharmaceutical company’s stock valued at $4,112,000 after purchasing an additional 1,445 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Royalty Pharma by 6.1% in the third quarter. Geode Capital Management LLC now owns 7,265,786 shares of the biopharmaceutical company’s stock valued at $205,562,000 after purchasing an additional 417,490 shares during the period. 54.35% of the stock is owned by institutional investors and hedge funds.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.